Pharmacological mechanisms contributing to the clinical efficacy of levosimendan

Z. Papp, Kálmán Csapó, Piero Pollesello, Heimo Haikala, I. Édes

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Acute decompensation of chronic heart failure is a direct life-threatening situation with short-term mortality approaching 30%. A number of maladaptive changes are amplified within the cardiovascular system during the progression of chronic heart failure that makes the decompensation phase difficult to handle. Levosimendan is a new Ca2+-sensitizer for the treatment of acutely decompensated heart failure that has proved to be effective during the decompensation of chronic heart failure and acute myocardial infarction. Levosimendan differs from other cardiotonic agents that are used for acute heart failure in that it utilizes a unique dual mechanism of action: Ca 2+-sensitization through binding to troponin C in the myocardium, and the opening of ATP-sensitive K+ channels in vascular smooth muscle. In general, these mechanisms evoke positive inotropy and vasodilation. Clinical studies suggested long-term benefits on mortality following short-term administration. It may, therefore, be inferred that levosimendan has additional effects on the cardiovascular system that are responsible for the prolongation of survival. Results of pre-clinical and clinical investigations suggest that the combination of levosimendan-induced cardiac and vascular changes has favorable effects on the coronary, pulmonary and peripheral circulations. Redistribution of the circulating blood offers an improved hemodynamic context for the development of a positive inotropic effect through Ca 2+-sensitization of the contractile filaments, without a proportionate increase in myocardial oxygen consumption or the development of arrhythmias. Activation of ATP-sensitive K+ channels, both on sarcolemma and mitochondria, may protect against myocardial ischemia, and decreased levels of cytokines may prevent the development of further myocardial remodeling. Collectively, these effects of levosimendan shift the disturbed cardiovascular parameters towards normalization, thereby halting the perpetuation of the vicious cycle of heart failure progression. This may contribute to stabilization of the circulation and improved life expectancy of patients with chronic heart failure.

Original languageEnglish
Pages (from-to)71-98
Number of pages28
JournalCardiovascular Drug Reviews
Volume23
Issue number1
Publication statusPublished - 2005

Fingerprint

Heart Failure
Pharmacology
Cardiovascular System
Adenosine Triphosphate
Troponin C
Cardiotonic Agents
Sarcolemma
Pulmonary Circulation
Mortality
Life Expectancy
simendan
Vascular Smooth Muscle
Vasodilation
Oxygen Consumption
Myocardial Ischemia
Blood Vessels
Cardiac Arrhythmias
Myocardium
Mitochondria
Hemodynamics

Keywords

  • Ca-sensitization
  • Cardiotonic agents
  • Heart failure
  • Levosimendan
  • OR-1896
  • Postive inotropy

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. / Papp, Z.; Csapó, Kálmán; Pollesello, Piero; Haikala, Heimo; Édes, I.

In: Cardiovascular Drug Reviews, Vol. 23, No. 1, 2005, p. 71-98.

Research output: Contribution to journalArticle

Papp, Z. ; Csapó, Kálmán ; Pollesello, Piero ; Haikala, Heimo ; Édes, I. / Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. In: Cardiovascular Drug Reviews. 2005 ; Vol. 23, No. 1. pp. 71-98.
@article{5520a36dfe234af28e04093e41090004,
title = "Pharmacological mechanisms contributing to the clinical efficacy of levosimendan",
abstract = "Acute decompensation of chronic heart failure is a direct life-threatening situation with short-term mortality approaching 30{\%}. A number of maladaptive changes are amplified within the cardiovascular system during the progression of chronic heart failure that makes the decompensation phase difficult to handle. Levosimendan is a new Ca2+-sensitizer for the treatment of acutely decompensated heart failure that has proved to be effective during the decompensation of chronic heart failure and acute myocardial infarction. Levosimendan differs from other cardiotonic agents that are used for acute heart failure in that it utilizes a unique dual mechanism of action: Ca 2+-sensitization through binding to troponin C in the myocardium, and the opening of ATP-sensitive K+ channels in vascular smooth muscle. In general, these mechanisms evoke positive inotropy and vasodilation. Clinical studies suggested long-term benefits on mortality following short-term administration. It may, therefore, be inferred that levosimendan has additional effects on the cardiovascular system that are responsible for the prolongation of survival. Results of pre-clinical and clinical investigations suggest that the combination of levosimendan-induced cardiac and vascular changes has favorable effects on the coronary, pulmonary and peripheral circulations. Redistribution of the circulating blood offers an improved hemodynamic context for the development of a positive inotropic effect through Ca 2+-sensitization of the contractile filaments, without a proportionate increase in myocardial oxygen consumption or the development of arrhythmias. Activation of ATP-sensitive K+ channels, both on sarcolemma and mitochondria, may protect against myocardial ischemia, and decreased levels of cytokines may prevent the development of further myocardial remodeling. Collectively, these effects of levosimendan shift the disturbed cardiovascular parameters towards normalization, thereby halting the perpetuation of the vicious cycle of heart failure progression. This may contribute to stabilization of the circulation and improved life expectancy of patients with chronic heart failure.",
keywords = "Ca-sensitization, Cardiotonic agents, Heart failure, Levosimendan, OR-1896, Postive inotropy",
author = "Z. Papp and K{\'a}lm{\'a}n Csap{\'o} and Piero Pollesello and Heimo Haikala and I. {\'E}des",
year = "2005",
language = "English",
volume = "23",
pages = "71--98",
journal = "Cardiovascular Drug Reviews",
issn = "0897-5957",
publisher = "Neva Press, Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacological mechanisms contributing to the clinical efficacy of levosimendan

AU - Papp, Z.

AU - Csapó, Kálmán

AU - Pollesello, Piero

AU - Haikala, Heimo

AU - Édes, I.

PY - 2005

Y1 - 2005

N2 - Acute decompensation of chronic heart failure is a direct life-threatening situation with short-term mortality approaching 30%. A number of maladaptive changes are amplified within the cardiovascular system during the progression of chronic heart failure that makes the decompensation phase difficult to handle. Levosimendan is a new Ca2+-sensitizer for the treatment of acutely decompensated heart failure that has proved to be effective during the decompensation of chronic heart failure and acute myocardial infarction. Levosimendan differs from other cardiotonic agents that are used for acute heart failure in that it utilizes a unique dual mechanism of action: Ca 2+-sensitization through binding to troponin C in the myocardium, and the opening of ATP-sensitive K+ channels in vascular smooth muscle. In general, these mechanisms evoke positive inotropy and vasodilation. Clinical studies suggested long-term benefits on mortality following short-term administration. It may, therefore, be inferred that levosimendan has additional effects on the cardiovascular system that are responsible for the prolongation of survival. Results of pre-clinical and clinical investigations suggest that the combination of levosimendan-induced cardiac and vascular changes has favorable effects on the coronary, pulmonary and peripheral circulations. Redistribution of the circulating blood offers an improved hemodynamic context for the development of a positive inotropic effect through Ca 2+-sensitization of the contractile filaments, without a proportionate increase in myocardial oxygen consumption or the development of arrhythmias. Activation of ATP-sensitive K+ channels, both on sarcolemma and mitochondria, may protect against myocardial ischemia, and decreased levels of cytokines may prevent the development of further myocardial remodeling. Collectively, these effects of levosimendan shift the disturbed cardiovascular parameters towards normalization, thereby halting the perpetuation of the vicious cycle of heart failure progression. This may contribute to stabilization of the circulation and improved life expectancy of patients with chronic heart failure.

AB - Acute decompensation of chronic heart failure is a direct life-threatening situation with short-term mortality approaching 30%. A number of maladaptive changes are amplified within the cardiovascular system during the progression of chronic heart failure that makes the decompensation phase difficult to handle. Levosimendan is a new Ca2+-sensitizer for the treatment of acutely decompensated heart failure that has proved to be effective during the decompensation of chronic heart failure and acute myocardial infarction. Levosimendan differs from other cardiotonic agents that are used for acute heart failure in that it utilizes a unique dual mechanism of action: Ca 2+-sensitization through binding to troponin C in the myocardium, and the opening of ATP-sensitive K+ channels in vascular smooth muscle. In general, these mechanisms evoke positive inotropy and vasodilation. Clinical studies suggested long-term benefits on mortality following short-term administration. It may, therefore, be inferred that levosimendan has additional effects on the cardiovascular system that are responsible for the prolongation of survival. Results of pre-clinical and clinical investigations suggest that the combination of levosimendan-induced cardiac and vascular changes has favorable effects on the coronary, pulmonary and peripheral circulations. Redistribution of the circulating blood offers an improved hemodynamic context for the development of a positive inotropic effect through Ca 2+-sensitization of the contractile filaments, without a proportionate increase in myocardial oxygen consumption or the development of arrhythmias. Activation of ATP-sensitive K+ channels, both on sarcolemma and mitochondria, may protect against myocardial ischemia, and decreased levels of cytokines may prevent the development of further myocardial remodeling. Collectively, these effects of levosimendan shift the disturbed cardiovascular parameters towards normalization, thereby halting the perpetuation of the vicious cycle of heart failure progression. This may contribute to stabilization of the circulation and improved life expectancy of patients with chronic heart failure.

KW - Ca-sensitization

KW - Cardiotonic agents

KW - Heart failure

KW - Levosimendan

KW - OR-1896

KW - Postive inotropy

UR - http://www.scopus.com/inward/record.url?scp=17644369589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644369589&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 71

EP - 98

JO - Cardiovascular Drug Reviews

JF - Cardiovascular Drug Reviews

SN - 0897-5957

IS - 1

ER -